CancerX shared on LinkedIn:
“CancerX and OncoLens convened health system, life sciences, patient advocacy, and federal leaders across two sessions in 2026.
The group converged on one clear message:
Getting the right data to the right decision-maker at the right time is the most immediate and actionable lever for improvising cancer outcomes.
Key takeaways from the report:
- Data failure is clinical failure. A 4-week treatment delay alone raises the risk of death by 6–13%.
- The point of decision is the entry point. Surfacing trial and biomarker data when treatment is chosen raised one health system’s trial accrual to over 30%.
- Today’s fixes are manual and reactive. Nurse navigators, phone calls, PDFs, and CDs are covering structural gaps.
- Progress requires cross-sector infrastructure. No single stakeholder can solve this alone.
The report also lays out what each stakeholder, from health systems and pharma sponsors to digital health companies and federal partners, can do now.
Other articles about CancerX on OncoDaily.
